Takara board opposes all six ValueAct proposals for 16 December meeting
Takara Holdings' board opposes all six ValueAct proposals for a 16 December meeting, arguing the three outside directors targeted, elected with about 94% support in June, are needed to decide whether to keep its CDMO and gene medicine businesses.